Clinical Trials
5 trialsNCT04201262 2025-10-14
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02003144 2022-08-23
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT01892345 2019-06-26
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Terminated
NCT02398994 2016-07-20
STRIVE
Guy's and St Thomas' NHS Foundation Trust
Phase 3 Terminated
NCT00004645 2005-06-24
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
Office of Rare Diseases (ORD)
Phase 3 Unknown